Skip to content

A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis

A Study to Evaluate the Efficacy and Safety of an Experimental Solution for Peritoneal Dialysis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00214721
Enrollment
120
Registered
2005-09-22
Start date
2005-02-28
Completion date
2006-07-31
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease

Brief summary

Objective: The purpose of this study is to demonstrate: -the non-inferiority of an experimental peritoneal dialysis solution compared to a current solution for the management of end stage renal disease (ESRD) in peritoneal dialysis patients.

Interventions

Sponsors

Baxter Healthcare Corporation
CollaboratorINDUSTRY
Vantive Health LLC
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who have given written informed consent after the nature of the study has been explained. * Patients who are at least 18 years of age. * Patients who have been treated with CAPD using specific solutions for at least 60 days before the baseline visit.

Exclusion criteria

* Patients who have received antibiotics for the treatment of an episode of peritonitis within 30 days before the screening visit. - Patients who have had acute or chronic exit-site or tunnel infection in the past 14 days, counted from the last day of infection to the screening visit. * Patients who have other serious diseases, such as active, or if previously treated, residual malignancy or systemic infection. * Patients who have had a major illness or injury requiring hospitalisation within 30 days before the baseline visit. * Patients who have severe malnutrition (serum albumin \< 25 g/l by bromocresol green method). * Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted. * Patients who have received an investigational product within 30 days preceding the screening visit. * Patients who are pregnant or lactating. (NB: Female patients of childbearing potential must have a negative urine or serum pregnancy test at the time of the screening and will be required to use a medically acceptable means of contraception during their participation in this study). * Patients who have a significant psychiatric disorder or mental disability that could interfere with his/her ability to provide informed consent and/or comply with protocol procedures.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026